NEW OPTION FOR MANAGEMENT OF HIGH-RISK SOFT TISSUE SARCOMA OF THE LIMB International, multi-centre sarcoma trial shows benefits of integrating immunotherapy with radiotherapy and surgery
The Australia and New Zealand Sarcoma Association (ANZSA) is the peak body for the sarcoma community. ANZSA aims to improve outcomes for sarcoma patients through research, education and awareness of sarcomas and related tumours.
ANZSA fosters effective collaborations across multi-disciplinary teams (MDT), which comprise of specialist health professionals (including pathologists, radiologists, surgeons, radiation oncologists, medical oncologists and paediatric oncologists) working together to discuss sarcoma and related tumours cases, and how to best manage treatment and care.
Professor Angela Hong MBBS, MMed, PhD, FRANZCR is the co-Chair of ANZSA’s Scientific Advisory Committee and a Professor at Sydney Medical School of the University of Sydney. She is a radiation oncologist and has been a member of the Multidisciplinary Bone and Soft Tissue Tumour Clinic at Royal Prince Alfred Hospital/Chris O’Brien Lifehouse for the past 15 years.
As a clinician scientist, her research focuses on developing innovative radiation therapy technique and combination treatments to improve the outcome for patients with sarcoma.
Professor Hong spoke to Australian Health Journal about sarcoma and a recently concluded international, multicentre trial, that could lead to a new potential option for patients grappling with high-risk sarcoma of the limb.
Soft tissue sarcoma, a rare aggressive cancer originating in connective tissues, can affect both children and adults. It is particularly challenging to conduct clinical trials due to its rarity, However a recently concluded international collaborative Phase II clinical trial SARC032 has shown groundbreaking findings into the advantages of Immunotherapy for patients with high-risk soft tissue sarcoma of the limb
The trial was led by the Sarcoma Alliance Research Collaboration (SARC) in the United States and the Australia and New Zealand Sarcoma Association (ANZSA) in Australia. The Australian participating sites in the trial were Peter MacCallum Cancer Centre, Chris O’Brien Lifehouse and Princess Alexandra Hospital.
SARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb.
Professor Angela Hong, Australia’s Principal Investigator for the trial, believes these results will be beneficial for patients for this specific stage of sarcoma.
“This is a significant milestone. The integration of immunotherapy into standard treatment protocols heralds a new era in sarcoma management, offering patients and clinicians a potent tool in the battle against this formidable disease.”
-
Report: Youth pathways to health services
The 2020 Youth Health Forum (YHF) was created to make young people’s ideas and experiences part of our national discussions about services for young Australians.
Healthcare professionals across Australia have long recognised the problem of young people falling through the gaps of a health system that wasn’t designed for them.
-
Improving access to osteopathic services and integrated care models
The Chief Executive Officer of Osteopathy Australia, Antony Nicholas spoke with Australian Health Journal about:
– Involvement in the Strengthening Medicare Task Force
– The unique skills osteopaths have that can address the chronic disease burden
– Current workforce issues around osteopaths and if enough are coming through via student placements
– How uploading data to My Health Record by osteopaths could assist team-based care of patients
– How the value of osteopaths in Residential Aged Care Facilities (RACFs) could be better understood and better access for residents
– The recommendations around aged care access to allied health services, including osteopathy
– The recommendations around consumer access to osteopaths and GP referrals
– Other osteopathy recommendations in the upcoming Federal BudgetIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
-
Australian Healthcare Week
Held 27th-28th March at the ICC Sydney, the expo is one of the largest, if not the largest healthcare events in the regions. AHJ as media partner attended and met with delegates, exhibitors and leaders in the healthcare industry. Click the post to see footage.
